This book provides a comprehensive overview of the development of metabolic syndrome, the underlying mechanisms and therapeutic strategies for drug development. The authors examine the context of underlying molecular pathways and integrated physiology, then expanding the discussion to diseases associated with metabolic syndrome. The development of drug therapies for these diseases and complications is extensively covered. The book offers a comprehensive and in depth view of energy metabolism, metabolic tissues and pathways, molecular mechanism based drug discovery and clinical implications.
This book provides a comprehensive overview of the development of metabolic syndrome, the underlying mechanisms and therapeutic strategies for drug development. The authors examine the context of underlying molecular pathways and integrated physiology, then expanding the discussion to diseases associated with metabolic syndrome. The development of drug therapies for these diseases and complications is extensively covered. The book offers a comprehensive and in depth view of energy metabolism, metabolic tissues and pathways, molecular mechanism based drug discovery and clinical implications.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
MINGHAN "MING" WANG, PHD is Director and head of a metabolism group in Metabolic Disorders Research at Amgen. He has authored over forty publications and is a regular speaker at drug discovery conferences.
Inhaltsangabe
Introduction ix Minghan Wang Contributors xi Part One The Physiology of Metabolic Tissues Under Normal and Disease States 1. Gut as an Endocrine Organ: the Role of Nutrient Sensing in Energy Metabolism 3 Minghan Wang 2. Central Glucose Sensing and Control of Food Intake and Energy Homeostasis 29 Lourdes Mounien and Bernard Thorens 3. Abnormalities in Insulin Secretion in Type 2 Diabetes Mellitus 53 Taly Meas and Pierre-Jean Guillausseau 4. Adipokine Production by Adipose Tissue: A Novel Target for Treating Metabolic Syndrome and its Sequelae 73 Vanessa DeClercq, Danielle Stringer, Ryan Hunt, Carla G. Taylor, and Peter Zahradka 5. Hepatic Metabolic Dysfunctions in Type 2 Diabetes: Insulin Resistance and Impaired Glucose Production and Lipid Synthesis 133 Ruojing Yang 6. Energy Metabolism in Skeletal Muscle and its Link to Insulin Resistance 157 Minghan Wang Part Two Metabolic Diseases and Current Therapies 7. Mechanisms and Complications of Metabolic Syndrome 179 Minghan Wang 8. Emerging Therapeutic Approaches for Dyslipidemias Associated with High LDL and Low HDL 199 Margrit Schwarz and Jae B. Kim 9. Mechanism of Action of Niacin: Implications for Atherosclerosis and Drug Discovery 235 Devan Marar, Shobha H. Ganji, Vaijinath S. Kamanna, and Moti L. Kashyap 10. Current Antidiabetic Therapies and Mechanisms 253 Minghan Wang Part Three Drug Targets for Antidiabetic Therapies 11. GLP-1 Biology, Signaling Mechanisms, Physiology, and Clinical Studies 281 Remy Burcelin, Cendrine Cabou, Christophe Magnan, and Pierre Gourdy 12. Dipeptidyl Peptidase IV Inhibitors for Treatment of Diabetes 327 C.H.S. McIntosh, S.-J. Kim, R.A. Pederson, U. Heiser, and H.-U. Demuth 13. Sodium Glucose Cotransporter 2 Inhibitors 359 Margaret Ryan and Serge A. Jabbour 14. Fibroblast Growth Factor 21 as a Novel Metabolic Regulator 377 Radmila Micanovic, James D. Dunbar, and Alexei Kharitonenkov 15. Sirtuins as Potential Drug Targets for Metabolic Diseases 391 Qiang Tong 16. 11ß-Hydroxysteroid Dehydrogenase Type 1 as a Therapeutic Target for Type 2 Diabetes 423 Clarence Hale and David J. St. Jean, Jr. 17. Monoclonal Antibodies for the Treatment of Type 2 Diabetes: A Case Study with Glucagon Receptor Blockade 459 Hai Yan, Wei Gu, and Murielle Veniant-Ellison Part Four Lessons Learned and Future Outlook 18. Drug Development for Metabolic Diseases: Past, Present and Future 471 Minghan Wang Index 489
Introduction ix Minghan Wang Contributors xi Part One The Physiology of Metabolic Tissues Under Normal and Disease States 1. Gut as an Endocrine Organ: the Role of Nutrient Sensing in Energy Metabolism 3 Minghan Wang 2. Central Glucose Sensing and Control of Food Intake and Energy Homeostasis 29 Lourdes Mounien and Bernard Thorens 3. Abnormalities in Insulin Secretion in Type 2 Diabetes Mellitus 53 Taly Meas and Pierre-Jean Guillausseau 4. Adipokine Production by Adipose Tissue: A Novel Target for Treating Metabolic Syndrome and its Sequelae 73 Vanessa DeClercq, Danielle Stringer, Ryan Hunt, Carla G. Taylor, and Peter Zahradka 5. Hepatic Metabolic Dysfunctions in Type 2 Diabetes: Insulin Resistance and Impaired Glucose Production and Lipid Synthesis 133 Ruojing Yang 6. Energy Metabolism in Skeletal Muscle and its Link to Insulin Resistance 157 Minghan Wang Part Two Metabolic Diseases and Current Therapies 7. Mechanisms and Complications of Metabolic Syndrome 179 Minghan Wang 8. Emerging Therapeutic Approaches for Dyslipidemias Associated with High LDL and Low HDL 199 Margrit Schwarz and Jae B. Kim 9. Mechanism of Action of Niacin: Implications for Atherosclerosis and Drug Discovery 235 Devan Marar, Shobha H. Ganji, Vaijinath S. Kamanna, and Moti L. Kashyap 10. Current Antidiabetic Therapies and Mechanisms 253 Minghan Wang Part Three Drug Targets for Antidiabetic Therapies 11. GLP-1 Biology, Signaling Mechanisms, Physiology, and Clinical Studies 281 Remy Burcelin, Cendrine Cabou, Christophe Magnan, and Pierre Gourdy 12. Dipeptidyl Peptidase IV Inhibitors for Treatment of Diabetes 327 C.H.S. McIntosh, S.-J. Kim, R.A. Pederson, U. Heiser, and H.-U. Demuth 13. Sodium Glucose Cotransporter 2 Inhibitors 359 Margaret Ryan and Serge A. Jabbour 14. Fibroblast Growth Factor 21 as a Novel Metabolic Regulator 377 Radmila Micanovic, James D. Dunbar, and Alexei Kharitonenkov 15. Sirtuins as Potential Drug Targets for Metabolic Diseases 391 Qiang Tong 16. 11ß-Hydroxysteroid Dehydrogenase Type 1 as a Therapeutic Target for Type 2 Diabetes 423 Clarence Hale and David J. St. Jean, Jr. 17. Monoclonal Antibodies for the Treatment of Type 2 Diabetes: A Case Study with Glucagon Receptor Blockade 459 Hai Yan, Wei Gu, and Murielle Veniant-Ellison Part Four Lessons Learned and Future Outlook 18. Drug Development for Metabolic Diseases: Past, Present and Future 471 Minghan Wang Index 489
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
